Daratumumab, a monoclonal antibody to CD38, approved for the treatment of relapsed multiple myeloma as a single agent as well as in combination with lenalidomide or bortezomib, clearly shows activity in the treatment of patients with AL amyloidosis77 and appears to have a low-toxicity profile. The gene discussed is CD38; the disease is AL amyloidosis.